Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Chief Scientific Officer | September 14, 2020 | September 14, 2020 |
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Chief Scientific Officer | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date September 14, 2020 · Filed September 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,438 |
Reported balance
After 2020-09-14 transaction · row 1
1 source rowRow 1 · 2020-09-14 · Exercise / conversion · Acquired 6,350 · Balance 133,438 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2029-01-21 | Direct | 75,592 |
Reported balance
After 2020-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-14 · Exercise / conversion · Disposed 6,350 · Balance 75,592 F1: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.
Monte Rosa Therapeutics, Inc.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.71 · Expires 2034-01-01 | Direct | 119,000 |
Reported balance
After 2024-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-02 · Grant · Acquired 119,000 · Balance 119,000 F2: 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 5,266 |
Reported balance
Holding disclosure · report date 2024-01-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,266 F1: Includes an aggregate of 5,266 shares previously acquired under the Issuer's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 5,266 shares previously acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F2: 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 4, 2024 16:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 119,000 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001209191-24-000768 · doc4.xml · derivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 119,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 16:31 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-23-000958 · doc4.xml · derivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 18:32 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 117,450 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0000899243-22-008681 · doc4.xml · derivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,450 Underlying: Common Stock · 117,450 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 17:00 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 113,298 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025984 · doc4.xml · derivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,298 Underlying: Common Stock · 113,298 shares Expires 2031-06-22 F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 12, 2021 Filed Jun 25, 2021 17:00 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 387,069 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0000899243-21-025984 · doc4.xml · derivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,069 Underlying: Common Stock · 387,069 shares Expires 2031-04-12 F1 · derivative.exercise_price: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 8, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. F1 · derivative.underlying_shares: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
| September 14, 2020 Filed Sep 14, 2020 20:19 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 6,350 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-024982 · doc4.xml · derivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,592 Underlying: Common Stock · 6,350 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| September 14, 2020 Filed Sep 14, 2020 20:19 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 6,350 | $7.84 | $49,784.00 |
DisclosureSEC source: 0000899243-20-024982 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2020 Filed Jul 9, 2020 20:18 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 2,951 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-018817 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,942 Underlying: Common Stock · 2,951 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| July 08, 2020 Filed Jul 9, 2020 20:18 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 2,951 | $20.00 | $59,020.00 |
DisclosureSEC source: 0000899243-20-018817 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| July 08, 2020 Filed Jul 9, 2020 20:18 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 2,951 | $7.84 | $23,135.84 |
DisclosureSEC source: 0000899243-20-018817 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 20:39 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 141 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-018121 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,893 Underlying: Common Stock · 141 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 20:39 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 141 | $20.00 | $2,820.00 |
DisclosureSEC source: 0000899243-20-018121 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 20:39 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 141 | $7.84 | $1,105.44 |
DisclosureSEC source: 0000899243-20-018121 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 2,232 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-014719 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,034 Underlying: Common Stock · 2,232 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 2,232 | $20.00 | $44,640.00 |
DisclosureSEC source: 0000899243-20-014719 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 2,232 | $7.84 | $17,498.88 |
DisclosureSEC source: 0000899243-20-014719 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 448 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-014552 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,266 Underlying: Common Stock · 448 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 448 | $20.00 | $8,960.00 |
DisclosureSEC source: 0000899243-20-014552 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 448 | $7.84 | $3,512.32 |
DisclosureSEC source: 0000899243-20-014552 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 412 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-014416 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,714 Underlying: Common Stock · 412 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 412 | $20.00 | $8,240.00 |
DisclosureSEC source: 0000899243-20-014416 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 412 | $7.84 | $3,230.08 |
DisclosureSEC source: 0000899243-20-014416 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:23 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 6,088 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-005299 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,126 Underlying: Common Stock · 6,088 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:23 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 6,088 | $20.00 | $121,760.00 |
DisclosureSEC source: 0000899243-20-005299 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:23 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 6,088 | $7.84 | $47,729.92 |
DisclosureSEC source: 0000899243-20-005299 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:25 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 58,900 | $0.00 Strike: $16.87 | $0.00 |
DisclosureSEC source: 0000899243-20-002034 · doc4.xml · derivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,900 Underlying: Common Stock · 58,900 shares Expires 2030-01-22 F1 · derivative.exercise_date: This option was granted on January 23, 2020 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2020, subject to continued service. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 21:28 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 44,493 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-19-040973 · a4.xml · derivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,493 Underlying: Common Stock · 44,493 shares Expires 2029-07-17 F1 · derivative.exercise_date: The option was granted on July 18, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments from July 1, 2019 through June 30, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.